treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
evaluations relating to the
programs, personnel, and operations of the
Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel,2 solely for cybersecurity
purposes. All nonconfidential written
submissions will be available for public
inspection at the Office of the Secretary
and on EDIS.3

This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and on EDIS.3

SUMMARY: Patheon Pharmaceuticals Inc.
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTAL INFORMATION listed below
for further drug information.

DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before July 5, 2022. Such persons
may also file a written request for a
hearing on the application on or before
July 5, 2022.

ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.”

SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on February 3, 2022,
Patheon Pharmaceuticals Inc., 2110 East
Galbraith Road, Cincinnati, Ohio
45237–1625, applied to be registered as
a bulk manufacturer of the following basic
class(es) of controlled
substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamma Hydroxybutyric Acid</td>
<td>2010 I</td>
<td></td>
</tr>
</tbody>
</table>

The company plans to manufacture
the above-listed controlled substance as
Active Pharmaceutical Ingredient (API)
that will be further synthetized into
Food and Drug Administration-
approved dosage forms. No other
activities for this drug code are
approved for this registration.

Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2022–09779 Filed 5–5–22; 8:45 am]
BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration
[Docket No. DEA–991]

Bulk Manufacturer of Controlled
Substances Application: Patheon
Pharmaceuticals Inc.

AGENCY: Drug Enforcement
Administration, Justice.

ACTION: Notice of application.

SUMMARY: Patheon Pharmaceuticals Inc.
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTAL INFORMATION listed below
for further drug information.

DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration

2 All contract personnel will sign appropriate
non-disclosure agreements.

3 Electronic Document Information System